Interventions: Patients entered a 4-week, open run-in period, receiving fluticasone propionate 50µg twice daily via a Diskus™ inhalation device. Patients whose asthma was well controlled ...

Fluticasone is a prescription corticosteroid for long-term treatment of respiratory disorders, such as asthma and COPD. It is not supposed to relieve sudden breathing problems, so it won’t replace a ...

Introduction: The incidence of asthma exacerbations in patients receiving salmeterol/fluticasone propionate (Seretide ... twice daily from a Diskus™ inhaler for a 4-week run-in period ...

Seretide (salmeterol xinafoate/fluticasone propionate ... Seretide is available both as a pMDI and in the Diskus dry powder inhaler, and is also approved for patients with chronic obstructive ...

ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and ...

announced today that the Central Drugs Standard Control Organisation (CDSCO) in India has approved Afrezza (insulin human) Inhalation Powder in adults. The CDSCO decision follows existing ...

New Delhi, Dec 11 (PTI) Drug maker Cipla on Wednesday said it has received approval from the Central Drugs Standard Control Organisation for the distribution and marketing of Afrezza inhalation powder ...

MannKind (MNKD) and Cipla announced that the Central Drugs Standard Control Organisation in India has approved Afrezza Inhalation Powder in adults. The CDSCO decision follows existing approvals in ...

Drug maker Cipla on Wednesday said it has received approval from the Central Drugs Standard Control Organisation for the distribution and marketing of Afrezza inhalation powder in India. Afrezza, a ...

announced today that the Central Drugs Standard Control Organisation (CDSCO) in India has approved Afrezza (insulin human) Inhalation Powder in adults. The CDSCO decision follows existing approvals in ...